

1. Record Nr.	UNINA9910141343103321
Titolo	ATTD 2011 Year Book : Advanced Technologies and Treatments for Diabetes // edited by Moshe Phillip, Tadej Battelino
Pubbl/distr/stampa	Chichester, West Sussex, UK ; ; Hoboken, N.J., : John Wiley & Sons, 2012
ISBN	1-280-58787-3 9786613617705 1-118-32151-0 1-118-32150-2 1-118-32152-9
Edizione	[3rd ed.]
Descrizione fisica	1 online resource (298 p.)
Altri autori (Persone)	PhillipMoshe BattelinoTadej
Disciplina	616.462 616.46206
Soggetti	Diabetes - Treatment Diabetics - Rehabilitation
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	ATTD 2011 Yearbook; Contents; List of Contributors; Preface; CHAPTER 1 Self-Monitoring of Blood Glucose; CHAPTER 2 Continuous Glucose Monitoring in 2011; CHAPTER 3 Insulin Pumps; CHAPTER 4 Closing the Loop; CHAPTER 5 New Insulins and Insulin Therapy; CHAPTER 6 New Ways of Insulin Delivery; CHAPTER 7 Using Health Information Technology to Prevent and Treat Diabetes; CHAPTER 8 Technology and Pregnancy; CHAPTER 9 Type 1 Diabetes Mellitus: Immune Intervention; CHAPTER 10 Advances in Exercise, Physical Activity and Diabetes Mellitus CHAPTER 11 Diabetes Technology and Treatment in the Paediatric Age Group CHAPTER 12 Diabetes Technology and the Human Factor; CHAPTER 13 New Medications for the Treatment of Diabetes; Index
Sommario/riassunto	The traditional agents for controlling the levels of glucose in the blood remain important therapies but they have their downside from the point of view of tolerability and side effects. Moreover, they appear not

to be able to counter the natural history deterioration of the disease in terms of the onset of diabetic-related complications. Recent years have seen an influx of new treatment therapies and technologies aimed at achieving better glycaemic control for diabetic patients such as liraglutide (Novo Nordisk) and saxagliptin (BMS/Astra-Zeneca) and insulin pumps, away from the more tradit
